Novavax (NVAX) Stock Forecast & Price Target

Novavax Inc. has slightly increased its fiscal year 2025 revenue guidance to a range of $1.04 billion to $1.06 billion, in part due to anticipated milestones and marketing authorization transfers, which reflect the company’s ongoing initiatives to enhance revenue streams. The company reported improved working capital of $544.7 million and lower-than-expected SG&A expenses of $32 million, indicating effective cost management practices that could enhance profitability. Additionally, Novavax anticipates substantial savings of approximately $230 million over the next 11 years from reduced lease liabilities and operating costs, further strengthening its financial position and operational efficiency.

Novavax Inc's negative outlook is influenced by several fundamental concerns, including a significant year-over-year revenue decline of 17% due to the transition of commercial responsibility to Sanofi, which is expected to impact future revenue generation. The company's cash equivalents have decreased to $778.2 million, down from $938.2 million by the end of 2024, indicating ongoing operational cash burn despite some offset from milestone payments and debt refinancing. Additionally, the potential failure of Novavax's vaccine candidates, such as NanoFlu, to differentiate themselves from existing alternatives poses a risk to their competitiveness and could further hinder the company's financial forecasts.